No Data
No Data
Truist Financial Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Announces Target Price $18
Baird Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $18
Wells Fargo Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $14
Voyager Says Joint Steering Committee With Collaborator Neurocrine Selected A Development Candidate In Gene Therapy Program; Selection Of Candidate Triggered $3M Milestone Payment
Express News | Voyager Advances Collaboration With Neurocrine; Third Gene Therapy Development Candidate Selected
Voyager Therapeutics: A Strong Buy on Gene Therapy Prospects and Strategic Novartis Partnership
No Data
No Data